Katherine Beachy, DVM Elizabeth Eilers, DVM Lynn Buzhardt, DVM Jason St. Romain, DVM Elizabeth A. Carroll, DVM Terry Clekis, DVM Jennifer DeBerry, DVM Keith Richter, DVM Elizabeth A. Dole, DVM Patrick S. Hackett, DVM Jennifer Bledsoe, DVM Jennifer L. Hodge, DVM Edward Jezbera, DVM Kristi Lively, DVM Maire S. Mahanes, DVM Alyce M. Meyer, DVM Douglas R. Santen, DVM Roger Sifferman, DVM Nancy L. Suska, DVM
(d) Investigators and Locations:
Purpose of Study: To confirm the effectiveness and safety of VETSULIN to reduce hyperglycemia and hyperglycemia-associated signs in cats with diabetes mellitus over a 60 day treatment period and to provide additional evidence of effectiveness and safety over a 180 day treatment period.
Description of Test Animals: The study included 78 client owned diabetic cats (53 male and 25 female - all neutered) representing various breeds ranging in age from 3 to 17.5 years and ranging in weight from 1.9 to 10.8 kg. A total of 77 cats were included in the analysis of effectiveness.
Control and Treatment Groups: In accordance with 21 CFR 514.117(b)(4)(iv), the effects of VETSULIN were compared with experience historically derived from the predictable history of diabetes mellitus in cats. All cats received treatment with VETSULIN. No control animals were used.